STOCK TITAN

MBX Biosciences, Inc. (MBX) grants CEO major option and RSU awards

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MBX Biosciences, Inc. reported equity awards to President and CEO Steven L. Hoerter on August 3, 2026. He received stock options for 331000.0000 shares of common stock at a $64.4100 exercise price, vesting 25% on July 13, 2027 and in 36 equal monthly installments thereafter, expiring August 3, 2036. He also received 71000.0000 restricted stock units vesting 25% annually each July 13 from 2027 through 2030. Following these grants he directly held 82938.0000 common shares, while 20000.0000 additional shares are held by the Steven L Hoerter Revocable Trust, with beneficial ownership disclaimed except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Hoerter Steven L.
Role President and CEO
Type Security Shares Price Value
Grant/Award Stock option (right to buy) F3 331,000 $0.00 $0.00
Grant/Award Common Stock F1 71,000 $0.00 $0.00
holding Common Stock F2 -- -- --
Holdings After Transaction: Stock option (right to buy) — 331,000 shares (Direct); Common Stock — 82,938 shares (Direct); Common Stock — 20,000 shares (Indirect, Trust)
Footnotes (3)
  1. F1. Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.
  2. F2. Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
  3. F3. The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.
Stock options granted 331000.0000 shares Stock option award to CEO on 2026-08-03
Option exercise price $64.4100 per share Exercise price for 331000.0000 stock options
Option expiration date 2036-08-03 Expiration of CEO stock option grant
RSUs granted 71000.0000 shares Restricted stock units granted to CEO on 2026-08-03
Direct common stock holdings 82938.0000 shares CEO direct common stock position following reported grants
Trust-held common shares 20000.0000 shares Shares held by the Steven L Hoerter Revocable Trust with beneficial ownership disclaimed
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"). 25% of the"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Revocable Trust financial
"Shares held by the Steven L Hoerter Revocable Trust dated"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
pecuniary interest financial
"disclaims beneficial ownership except to the extent of any pecuniary interest"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did MBX (MBX) grant to CEO Steven L. Hoerter?

Steven L. Hoerter received 331000.0000 stock options at a $64.4100 exercise price and 71000.0000 RSUs. The options and RSUs are compensation awards that vest over several years, tying a significant portion of his pay to MBX equity performance.

What is the vesting schedule for the new MBX (MBX) stock options?

The options vest with 25% of the shares on July 13, 2027, then in 36 equal monthly installments. This creates a roughly four-year vesting period, requiring continued service through each vesting date before the options become fully exercisable.

How do the MBX (MBX) restricted stock units granted to the CEO vest?

The 71000.0000 RSUs vest 25% on each July 13 in 2027, 2028, 2029 and 2030. Each annual vesting tranche requires Mr. Hoerter to remain in service on the applicable date before those shares of common stock are delivered.

How many MBX (MBX) common shares does Steven L. Hoerter hold after these grants?

After the awards, he directly holds 82938.0000 common shares. In addition, 20000.0000 shares are held by the Steven L Hoerter Revocable Trust, where he acts as trustee but disclaims beneficial ownership except for any pecuniary interest.

What are the key terms of the MBX (MBX) stock options granted to the CEO?

The options cover 331000.0000 shares at a $64.4100 exercise price and expire August 3, 2036. They vest over time beginning July 13, 2027, aligning Mr. Hoerter’s potential gains with longer-term MBX share performance.

Are any MBX (MBX) shares attributed to entities associated with the CEO?

Yes. 20000.0000 common shares are held by the Steven L Hoerter Revocable Trust. Mr. Hoerter serves as trustee and disclaims beneficial ownership of those shares except to the extent of any pecuniary interest in the trust holdings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hoerter Steven L.

(Last)(First)(Middle)
C/O MBX BIOSCIENCES INC.
11711 N. MERIDIAN STREET, SUITE 300

(Street)
CARMEL INDIANA 46032

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MBX Biosciences, Inc. [ MBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026A71,000(1)A$082,938D
Common Stock20,000ITrust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$64.4108/03/2026A331,000 (3)08/03/2036Common Stock331,000$0331,000D
Explanation of Responses:
1. Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.
2. Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
3. The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ John W. Smither, Attorney-in-Fact08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)